PACEBO protocol

chemotherapy protocol consisting of above compounds; used in the treatment of non-Hodgkin's lymphoma

Also Known As:

PAdriaCEBO protocol; cyclOBEAP regimen

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PACEBO protocol: 2
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PACEBO protocol: 2
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PACEBO protocol: 2
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        PACEBO protocol: 2
  - Glucosides: 639
    - Etoposide: 10706
      - PACEBO protocol: 2
- Glycoconjugates: 1353
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - PACEBO protocol: 2
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - PACEBO protocol: 2
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 562
        Etoposide: 10706
        PACEBO protocol: 2
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        Doxorubicin: 35390
        PACEBO protocol: 2
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        Phosphoramide Mustards: 5
        Cyclophosphamide: 25473
        PACEBO protocol: 2
- Organophosphorus Compounds: 300
  - Phosphoramides: 8
    - Phosphoramide Mustards: 5
      - Cyclophosphamide: 25473
        PACEBO protocol: 2
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        PACEBO protocol: 2
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        PACEBO protocol: 2
- Fused-Ring Compounds
  - Steroids: 70059
    - Pregnanes: 9
      - Pregnadienes
        Pregnadienetriols
        Prednisolone: 12013
        PACEBO protocol: 2
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vincristine: 9251
        PACEBO protocol: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        PACEBO protocol: 2
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        PACEBO protocol: 2

Experts

1.	Niitsu, Nozomi: 2 articles (06/2011 - 12/2006)
2.	Okamoto, Masataka: 2 articles (06/2011 - 12/2006)
3.	Hayama, Miyuki: 1 article (06/2011)
4.	Nakamine, Hirokazu: 1 article (06/2011)
5.	Nakamura, Shigeo: 1 article (06/2011)
6.	Tamaru, Jun-Ichi: 1 article (06/2011)
7.	Yoshino, Tadashi: 1 article (06/2011)
8.	Aoki, Sadao: 1 article (12/2006)
9.	Hirano, Masami: 1 article (12/2006)
10.	Kohori, Mika: 1 article (12/2006)

Related Diseases

1.	Lymphoma (Lymphomas) 12/01/2006 - "We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission." 12/01/2006 - "We treated elderly patients (65-69 years) who had aggressive lymphoma with the CyclOBEAP regimen, and we studied the safety and efficacy of this treatment. " 12/01/2006 - "Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma."
2.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 06/01/2011 - "Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers."

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)